StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.07+0.38 (+5.68%)

Close on Nov 18, 2026Market cap $466.98MP/E –Yield –

Evolus operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Evolus's operating income for the twelve months ending Jun 30, 2026 was -$18.67M. For fiscal 2025 it was -$32.66M. The highest annual figure on record is -$11.73M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.66M–
FY2024Dec 31, 2024-$34.41M–
FY2023Dec 31, 2023-$49.23M–
FY2022Dec 31, 2022-$65.33M–
FY2021Dec 31, 2021-$44.41M–
FY2020Dec 31, 2020-$153.07M–
FY2019Dec 31, 2019-$98.95M–
FY2018Dec 31, 2018-$46.14M–
FY2017Dec 31, 2017-$11.73M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.54M–
Q1 FY2026Mar 31, 2026-$6.85M–
Q4 FY2025Dec 31, 2025$4.22M–
Q3 FY2025Sep 30, 2025-$11.50M–
Q2 FY2025Jun 30, 2025-$10.21M–
Q1 FY2025Mar 31, 2025-$15.17M–
Q4 FY2024Dec 31, 2024-$2.31M–
Q3 FY2024Sep 30, 2024-$15.47M–
Q2 FY2024Jun 30, 2024-$7.70M–
Q1 FY2024Mar 31, 2024-$8.92M–
Q4 FY2023Dec 31, 2023-$8.64M–
Q3 FY2023Sep 30, 2023-$13.44M–
Q2 FY2023Jun 30, 2023-$15.12M–
Q1 FY2023Mar 31, 2023-$12.04M–
Q4 FY2022Dec 31, 2022-$10.64M–
Q3 FY2022Sep 30, 2022-$17.90M–
Q2 FY2022Jun 30, 2022-$21.35M–
Q1 FY2022Mar 31, 2022-$15.45M-292.5%
Q4 FY2021Dec 31, 2021-$18.03M–
Q3 FY2021Sep 30, 2021-$19.11M–
Q2 FY2021Jun 30, 2021-$15.29M–
Q1 FY2021Mar 31, 2021$8.03M–
Q4 FY2020Dec 31, 2020-$108.03M–
Q3 FY2020Sep 30, 2020-$8.76M–
Q2 FY2020Jun 30, 2020-$18.89M–
Q1 FY2020Mar 31, 2020-$17.40M–
Q4 FY2019Dec 31, 2019-$12.54M–
Q3 FY2019Sep 30, 2019-$25.14M–
Q2 FY2019Jun 30, 2019-$36.00M–
Q1 FY2019Mar 31, 2019-$25.27M–
Q4 FY2018Dec 31, 2018-$12.51M–
Q3 FY2018Sep 30, 2018-$11.49M–
Q2 FY2018Jun 30, 2018-$16.10M–
Q1 FY2018Mar 31, 2018-$6.05M–
Q4 FY2017Dec 31, 2017-$2.86M–
Q3 FY2017Sep 30, 2017-$2.62M–
Q2 FY2017Jun 30, 2017-$2.28M–
Q1 FY2017Mar 31, 2017-$3.98M–

More Evolus figures

See a number that looks wrong?